The Rising Potential of Nicotinamide for Glaucoma Prevention

Primary open-angle glaucoma (POAG) remains a leading cause of irreversible blindness globally, including in India. Currently, the standard of care focuses almost exclusively on lowering intraocular pressure. However, many patients continue to lose vision despite achieving target pressures. Therefore, researchers are looking for neuroprotective strategies that can prevent the conversion from ocular hypertension to glaucoma. Nicotinamide for glaucoma prevention has emerged as a promising metabolic intervention. A recent cohort study evaluating nearly 3,000 patients indicates that systemic nicotinamide supplementation may significantly reduce the risk of POAG diagnosis. Specifically, the study found a 66% reduction in the hazard ratio for patients taking this supplement compared to those who did not. This evidence suggests that metabolic support can play a vital role in protecting retinal ganglion cells from damage. Consequently, clinicians are increasingly interested in how vitamin B3 derivatives can support mitochondrial health in at-risk populations. Moreover, these findings highlight a potential shift in how we manage patients with ocular hypertension who are at high risk for progression.

Mitochondrial Health and the Pathophysiology of Glaucoma

To understand the benefits of nicotinamide, we must examine the underlying pathology of glaucoma. Retinal ganglion cells require immense amounts of energy to maintain their physiological functions. Because these cells are highly metabolic, they are particularly vulnerable to mitochondrial dysfunction. Notably, aging and elevated intraocular pressure are both associated with declining levels of nicotinamide adenine dinucleotide (NAD+). NAD+ is a critical coenzyme for mitochondrial energy production. When NAD+ levels fall, the cells become more susceptible to oxidative stress and metabolic failure. Consequently, providing a precursor like nicotinamide helps replenish these levels. This metabolic support effectively increases the resilience of the optic nerve. Laboratory models have previously shown that oral nicotinamide can prevent the majority of age-related gene expression changes within ganglion cells. Therefore, the transition from preclinical models to real-world clinical data is a significant milestone. This research confirms that metabolic intervention is not just theoretical but has practical applications in preventing neurodegeneration. Resultantly, focusing on cellular health alongside pressure control provides a more comprehensive approach to patient care.

Robust Study Design Using Real-World Federated Data

The evidence supporting nicotinamide for glaucoma prevention comes from a large cohort study utilizing a federated research network. This network involved 67 US health care organizations, providing a diverse and robust dataset. Researchers identified patients with ocular hypertension who were not yet receiving topical glaucoma therapies. They then compared patients documented as taking systemic nicotinamide to a control group. To ensure a fair comparison, the study utilized 1:1 propensity score matching. This method balanced baseline covariates such as age, sex, and comorbid conditions. Specifically, the final sample included 2,920 patients with a mean follow-up period of 3.7 years. By excluding those with a history of prior laser therapy or topical drops, the study isolated the effects of nicotinamide as a prophylactic measure. Furthermore, the use of deidentified electronic medical record data allowed for a broad analysis of real-world outcomes. This design is particularly valuable because it reflects how supplements are used in everyday clinical practice. Consequently, the results carry significant weight for clinicians looking for evidence-based adjunctive therapies to offer their patients.

Significant Reductions in Primary Open-Angle Glaucoma Conversion

The primary outcome of the study was the risk of receiving a formal diagnosis of primary open-angle glaucoma. The results were remarkably clear. In the nicotinamide group, only 3.5% of patients developed POAG over the follow-up period. In contrast, the control group saw a 9.0% conversion rate. This represents a hazard ratio of 0.34, which is statistically significant with a P-value of less than .001. Therefore, patients taking nicotinamide were approximately three times less likely to develop glaucoma. Notably, this protective effect remained consistent across various demographic subgroups. Additionally, the survival curves began to diverge early, suggesting that the benefits of supplementation may manifest relatively quickly. Such a significant reduction in conversion risk is rarely seen with non-IOP-lowering interventions. Consequently, this study provides strong evidence that nicotinamide for glaucoma prevention is an effective strategy for high-risk patients. These findings support the hypothesis that metabolic enhancement can prevent the permanent structural and functional damage associated with glaucoma. Moreover, it offers hope for a future where neuroprotection is a standard part of ophthalmic care.

Impact on Long-term Medical and Surgical Escalation

Beyond preventing the initial diagnosis, the study examined whether nicotinamide could delay the need for traditional treatments. Specifically, the researchers tracked the initiation of first-line topical glaucoma therapy and the requirement for laser trabeculoplasty. Notably, patients in the nicotinamide group were much less likely to start eye drops, with a hazard ratio of 0.42. Furthermore, the risk of requiring laser intervention was reduced by 65%, with a hazard ratio of 0.35. These secondary outcomes are clinically vital because they relate directly to the patient’s burden of care. Reducing the need for lifelong topical medications can improve quality of life and decrease side effects. Similarly, delaying surgical or laser interventions reduces the risk of procedural complications. Therefore, the benefits of nicotinamide extend beyond simple neuroprotection to tangible clinical milestones. Because the study focused on patients with ocular hypertension, these results suggest that early intervention is key. By supporting the metabolic health of the retina early, we can potentially alter the entire disease trajectory. Consequently, systemic supplementation could become a cost-effective way to reduce the overall surgical and medical burden in ophthalmology.

Practical Considerations for Ophthalmic Practice in India

For clinicians in India, these findings are particularly relevant given the high prevalence of glaucoma and the challenges of treatment adherence. Nicotinamide is generally affordable and widely available, making it a feasible adjunctive therapy. However, doctors must remain mindful of the correct dosage and potential side effects. While the study indicates a strong protective effect, systemic nicotinamide should not replace traditional intraocular pressure management. Instead, it should be viewed as a complementary approach. Specifically, patients with ocular hypertension who have additional risk factors may benefit most from this supplementation. Clinicians should also be aware of the importance of monitoring liver function, as very high doses of vitamin B3 derivatives can occasionally impact hepatic health. Furthermore, patient education is crucial to ensure they do not substitute supplements for prescribed eye drops. In conclusion, integrating nicotinamide for glaucoma prevention into clinical practice could significantly improve long-term outcomes for at-risk Indian patients. Ultimately, this research provides a strong foundation for a more holistic, neuroprotective-centered approach to managing ocular hypertension and preventing irreversible vision loss.

Is nicotinamide the same as niacin, and are they interchangeable?

While both nicotinamide and niacin are forms of Vitamin B3, they are not interchangeable in the context of glaucoma treatment. Niacin often causes significant skin flushing and has different metabolic effects, whereas nicotinamide is the amide derivative and is much better tolerated. Research focusing on neuroprotection specifically utilizes nicotinamide due to its direct role in the NAD+ salvage pathway within the retina. Consequently, patients should be advised to use only the nicotinamide form to ensure efficacy and minimize side effects.

What is the recommended dosage of nicotinamide for glaucoma neuroprotection?

Most clinical trials investigating neuroprotection use a daily dose of 1.5 grams to 3 grams of nicotinamide. This dosage is significantly higher than the standard recommended daily allowance for general nutrition. Therefore, it is essential that patients only take such amounts under medical supervision. Higher doses may require periodic monitoring of liver function tests to ensure safety. Clinicians should tailor the dose based on individual patient tolerance and the specific risk profile for glaucoma conversion or progression.

Can nicotinamide replace traditional eye drops for treating glaucoma?

No, nicotinamide cannot replace traditional intraocular pressure-lowering eye drops or laser treatments. Currently, the most effective way to slow glaucoma progression is by reducing eye pressure. Nicotinamide acts as an adjunctive, neuroprotective therapy that supports the health of the nerve cells rather than lowering the pressure itself. Therefore, it should be used in combination with standard treatments to provide a multi-faceted defense against the disease. Always consult with an ophthalmologist before making any changes to a prescribed glaucoma medication regimen.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

Muayad J et al. Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension. JAMA Ophthalmol. 2026 Jul 09. doi: 10.1001/jamaophthalmol.2026.2472. PMID: 42424069.

Hui F, et al. Improvement in inner retinal function with nicotinamide in glaucoma: A crossover randomized clinical trial. Clinical & Experimental Ophthalmology. 2020;48(7):903-914.

Williams PA, et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017;355(6326):756-760.

De Moraes CG, et al. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmology. 2022;140(1):11-18.